Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Recaticimab in Perioperative NSCLC
NCT06467617Phase 2Recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recaticimab in non-small cell lung cancer (NSCLC), sponsored by Beijing Chest Hospital. Primary endpoint: Pathologic Complete Response at 1.5 year. Started Aug 2024; status: recruiting.
02
Drugs
recaticimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06467617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467617.